Cencora, INC DEF 14A proxy statements

Cencora, Inc. announces its 2026 Annual Meeting of Shareholders to be held virtually on March 5, 2026, outlining key voting proposals.

Cencora achieved robust fiscal 2025 financial performance with 40% total shareholder return and $321.3 billion in revenue, driven by its pharmaceutical-centric strategy and key acquisitions.

Cencora, Inc. will hold its annual shareholder meeting virtually on March 6, 2025, and has released proxy materials for review and voting.

Cencora's proxy statement highlights the successful CEO transition, the addition of a new independent director, and a strong fiscal 2024 performance with $294.0 billion in revenue and a 26.2% total shareholder return.